Xeris Biopharma Holdings, Inc. XERS Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $111.75M+0.6% | $111.04M+21.2% | $91.6M+54.5% | $59.29M+1.4% | $58.44M-18.4% | ||
| $56.3M+10.3% | $51.05M-5.0% | $53.75M+1.3% | $53.05M+14.5% | $46.33M+14.6% | ||
| $74.23M+8.1% | $68.67M+1.8% | $67.46M+0.3% | $67.28M+27.7% | $52.69M+9.4% | ||
| $9.4M-1.5% | $9.55M-14.8% | $11.21M+87.9% | $5.96M-1.2% | $6.03M-19.0% | ||
| $251.68M+4.7% | $240.31M+7.3% | $224.02M+20.7% | $185.58M+13.5% | $163.49M-2.5% | ||
| $5.03M+1.8% | $4.95M0.0% | $4.95M-6.4% | $5.28M+0.5% | $5.26M-5.4% | ||
| $21.95M-0.7% | $22.11M-0.7% | $22.26M-0.6% | $22.4M-0.6% | $22.53M-0.5% | ||
| $22.86M0.0% | $22.86M0.0% | $22.86M0.0% | $22.86M0.0% | $22.86M0.0% | ||
| $85.37M-3.1% | $88.08M-3.0% | $90.79M-2.9% | $93.5M-2.8% | $96.21M-2.7% | ||
| $5.12M-1.9% | $5.22M-1.8% | $5.32M+5.0% | $5.06M-0.7% | $5.1M-5.7% | ||
| $392.01M+2.2% | $383.53M+3.6% | $370.19M+10.6% | $334.69M+6.1% | $315.45M-2.4% | ||
| $11.47M+273% | $3.08M-52.9% | $6.53M-31.0% | $9.46M+49.0% | $6.35M+177% | ||
| $4.35M-11.0% | $4.89M+84.6% | $2.65M+62.2% | $1.63M+947% | $156K-85.7% | ||
| $6.27M+0.6% | $6.23M+0.6% | $6.19M+0.6% | $6.16M+0.6% | $6.12M+0.6% | ||
| $118.59M+8.2% | $109.57M-5.7% | $116.2M+22.1% | $95.17M+0.1% | $95.07M-5.3% | ||
| $221.22M+0.4% | $220.34M+0.4% | $219.47M+0.4% | $218.63M+0.4% | $217.81M+0.4% | ||
| $31.06M-1.5% | $31.53M-1.4% | $31.99M-1.4% | $32.44M-1.3% | $32.87M-1.2% | ||
| $37.33M-1.1% | $37.76M-1.1% | $38.19M-1.1% | $38.6M-1.0% | $38.99M-0.9% | ||
| $8.13M-3.2% | $8.4M+148% | $3.39M-56.2% | $7.75M+60.4% | $4.83M+146% | ||
| $379M+2.5% | $369.84M-0.3% | $371.05M+4.8% | $353.99M+1.0% | $350.58M-0.6% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $18K+5.9% | $17K0.0% | $17K+6.3% | $16K0.0% | $16K+6.7% | ||
| $682.09M-0.4% | $685M+0.5% | $681.54M+2.7% | $663.71M+2.7% | $645.96M+0.6% | ||
| -$669.07M+0.3% | -$671.31M+1.6% | -$682.39M+0.1% | -$683.01M-0.3% | -$681.08M-1.4% | ||
| -$24K+4.0% | -$25K0.0% | -$25K-4.2% | -$24K+4.0% | -$25K0.0% | ||
| $13.01M-5.0% | $13.69M+1,690% | -$861K+95.5% | -$19.3M+45.0% | -$35.13M-18.6% | ||
| $392.01M+2.2% | $383.53M+3.6% | $370.19M+10.6% | $334.69M+6.1% | $315.45M-2.4% | ||
| $5.12M-1.9% | $5.22M-1.8% | $5.32M+5.0% | $5.06M-0.7% | $5.1M-5.7% | ||
| $21.95M-0.7% | $22.11M-0.7% | $22.26M-0.6% | $22.4M-0.6% | $22.53M-0.5% | ||
| $85.37M-3.1% | $88.08M-3.0% | $90.79M-2.9% | $93.5M-2.8% | $96.21M-2.7% | ||
| $21.95M-0.7% | $22.11M-0.7% | $22.26M-0.6% | $22.4M-0.6% | $22.53M-0.5% | ||
| $5.12M-1.9% | $5.22M-1.8% | $5.32M+5.0% | $5.06M-0.7% | $5.1M-5.7% | ||
| $21.95M-0.7% | $22.11M-0.7% | $22.26M-0.6% | $22.4M-0.6% | $22.53M-0.5% | ||
| $5.12M-1.9% | $5.22M-1.8% | $5.32M+5.0% | $5.06M-0.7% | $5.1M-5.7% | ||
| $32.29M-2.6% | $33.16M+9.2% | $30.35M+21.6% | $24.97M+24.5% | $20.05M-27.7% | ||
| $45.49M+5.2% | $43.25M-15.6% | $51.26M+54.6% | $33.17M+7.9% | $30.73M+5.7% | ||
| $32.29M-2.6% | $33.16M+9.2% | $30.35M+21.6% | $24.97M+24.5% | $20.05M-27.7% | ||
| $18.72M-1.3% | $18.97M-1.3% | $19.22M-2.9% | $19.78M+0.4% | $19.7M+3.3% | ||
| $4.35M-11.0% | $4.89M+84.6% | $2.65M+62.2% | $1.63M+947% | $156K-85.7% | ||
| $258.55M+0.2% | $258.1M+0.2% | $257.65M+0.2% | $257.22M-4.3% | $268.75M-1.0% | ||
| $18K+5.9% | $17K0.0% | $17K+6.3% | $16K0.0% | $16K+6.7% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $9.4M-1.5% | $9.55M-14.8% | $11.21M+87.9% | $5.96M-1.2% | $6.03M-19.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Xeris Biopharma Holdings, Inc.'s total assets?
- Xeris Biopharma Holdings, Inc. (XERS) holds $392.0M in total assets, up 24.3% year over year.
- How much debt does Xeris Biopharma Holdings, Inc. have?
- Xeris Biopharma Holdings, Inc. carries $258.6M in total debt against $13.0M of shareholders' equity, a debt-to-equity ratio of 19.87.
- How much cash does Xeris Biopharma Holdings, Inc. have?
- Xeris Biopharma Holdings, Inc. holds $111.8M in cash and equivalents.
- Can Xeris Biopharma Holdings, Inc. cover its short-term obligations?
- Its current ratio is 2.12 — current assets exceed current liabilities.
- Where does Xeris Biopharma Holdings, Inc.'s balance sheet data come from?
- Every line is extracted from Xeris Biopharma Holdings, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
